Establishing the lysine-rich protein CEST reporter gene as a CEST MR imaging detector for oncolytic virotherapy

Radiology

Volumn 275, Issue 3, 2015, Pages 746-754

  Farrar, Christian T ^a   Buhrman, Jason S ^a   Liu, Guanshu ^b,c   Kleijn, Anne ^a,d   Lamfers, Martine L M ^d   McMahon, Michael T ^b,c   Gilad, Assaf A ^b,c,e   Fulci, Giulia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 47DELTA; G 47DELTA LYSINE RICH PROTEIN; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG; LYSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL LYSATE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; GENETIC ENGINEERING; GLIOMA; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; TRANSGENE; VIRUS REPLICATION; ANIMAL; CELL CULTURE; FISCHER 344 RAT; PROCEDURES; SIMPLEXVIRUS;

ANIMALS; CELLS, CULTURED; GENES, REPORTER; LYSINE; MAGNETIC RESONANCE IMAGING; MALE; ONCOLYTIC VIROTHERAPY; RATS; RATS, INBRED F344; SIMPLEXVIRUS;

EID: 84929651864     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140251     Document Type: Article

References (29)

1. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 2008;10:391-411.
2. van Zijl PC, Yadav NN. Chemical exchange saturation transfer (CEST): what is in a name and what isn't? Magn Reson Med 2011;65(4):927-948.
3. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 2007;25(2):217-219.
4. Fulci G, Chiocca EA. The status of gene therapy for brain tumors. Expert Opin Biol Ther 2007;7(2):197-208.
5. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30(7):658-670.
6. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19(3):329-336.
7. Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther 2011;19(4):627-628.
8. Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 2006;103(34):12873-12878.
9. Dispenzieri A. Vaccine therapy with or without cyclophosphamide in treating patients with recurrent or refractory multiple myeloma. ClinicalTrials.gov: NCT00450814. Rochester, Minn: Mayo Clinic, 2007-2014.
10. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001;98(11):6396-6401.
11. Todo T. A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive glioblastoma. Japan: Japan Primary Registries Network (Internet), Wako-shi (Saitama), National Institute of Public Health; 2009. http://appswhoint/trialsearch/trialaspx?trialid=JPRN-UMIN000002661. 2008 Oct 16. Identifier JPRN-UMIN000002661.
12. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11(2):214-223.
13. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 2006;6:40.
14. Ma Y, Wang N, Li M, et al. Human CMV transcripts: an overview. Future Microbiol 2012;7(5):577-593.
15. Kim M, Gillen J, Landman BA, Zhou J, van Zijl PC. Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn Reson Med 2009;61(6):1441-1450.
16. de Graaf RA, Brown PB, McIntyre S, Nixon TW, Behar KL, Rothman DL. High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo. Magn Reson Med 2006;56(2):386-394.
17. Paxinos G, Watson CR, Emson PC. AChEstained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980;3(2):129-149.
18. Liu G, Gilad AA, Bulte JW, van Zijl PC, Mc-Mahon MT. High-throughput screening of chemical exchange saturation transfer MR contrast agents. Contrast Media Mol Imaging 2010;5(3):162-170.
19. Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 2003;50(6):1120-1126.
20. Augustinack JC, Helmer K, Huber KE, Kakunoori S, Zöllei L, Fischl B. Direct visualization of the perforant pathway in the human brain with ex vivo diffusion tensor imaging. Front Hum Neurosci 2010;4:42.
21. Alauddin MM, Conti PS. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998;25(3):175-180.
22. Yaghoubi S, Barrio JR, Dahlbom M, et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 2001;42(8):1225-1234.
23. Buursma AR, Rutgers V, Hospers GA, Mulder NH, Vaalburg W, de Vries EF. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl Med Commun 2006;27(1):25-30.
24. de Vries EF, van Waarde A, Harmsen MC, Mulder NH, Vaalburg W, Hospers GA. [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl Med Biol 2000;27(2):113-119.
25. Yadav NN, Jones CK, Xu J, et al. Detection of rapidly exchanging compounds using on-resonance frequency-labeled exchange (FLEX) transfer. Magn Reson Med 2012;68(4):1048-1055.
26. Yadav NN, Jones CK, Hua J, Xu J, van Zijl PC. Imaging of endogenous exchangeable proton signals in the human brain using frequency labeled exchange transfer imaging. Magn Reson Med 2013;69(4):966-973.
27. McMahon MT, Gilad AA, Zhou J, Sun PZ, Bulte JW, van Zijl PC. Quantifying exchange rates in chemical exchange saturation transfer agents using the saturation time and saturation power dependencies of the magnetization transfer effect on the magnetic resonance imaging signal (QUEST and QUESP): Ph calibration for poly-L-lysine and a starburst dendrimer. Magn Reson Med 2006;55(4):836-847.
28. Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 2011;17(1):130-134.
29. McMahon MT, Gilad AA, DeLiso MA, Berman SM, Bulte JW, van Zijl PC. New "multicolor" polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI. Magn Reson Med 2008;60(4):803-812.